Aurinia Pharmaceuticals Inc AUPH:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/26/23 EST
9.20quote price arrow down-0.01 (-0.11%)
Volume
34,671
Close
9.21UNCH (UNCH)
Volume
3,054,064
52 week range
4.07 - 20.48
Loading...
  • Open9.23
  • Day High9.30
  • Day Low8.95
  • Prev Close9.21
  • 52 Week High20.48
  • 52 Week High Date02/16/22
  • 52 Week Low4.07
  • 52 Week Low Date12/28/22

Key Stats

  • Market Cap1.309B
  • Shares Out142.11M
  • 10 Day Average Volume3.26M
  • Dividend-
  • Dividend Yield-
  • Beta1.08
  • YTD % Change113.19

KEY STATS

  • Open9.23
  • Day High9.30
  • Day Low8.95
  • Prev Close9.21
  • 52 Week High20.48
  • 52 Week High Date02/16/22
  • 52 Week Low4.07
  • 52 Week Low Date12/28/22
  • Market Cap1.309B
  • Shares Out142.11M
  • 10 Day Average Volume3.26M
  • Dividend-
  • Dividend Yield-
  • Beta1.08
  • YTD % Change113.19

RATIOS/PROFITABILITY

  • EPS (TTM)-0.83
  • P/E (TTM)-11.10
  • Fwd P/E (NTM)-9.21
  • EBITDA (TTM)-112.90M
  • ROE (TTM)-32.00%
  • Revenue (TTM)128.999M
  • Gross Margin (TTM)96.29%
  • Net Margin (TTM)-89.50%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date02/27/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aurinia Pharmaceuticals Inc

 

Profile

MORE
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a...
George Milne Ph.D.
Independent Chairman of the Board
Peter Greenleaf
President, Chief Executive Officer, Director
Joe Miller
Chief Financial Officer
Matthew Donley
Executive Vice President, Operations and Strategy
Volker Knappertz M.D.
Executive Vice President - Research and Development
Address
1203-4464 Markham St
Victoria, BC
V8Z 7X8
Canada

Top Peers

SYMBOLLASTCHG%CHG
BLU
BELLUS Health Inc
8.08UNCHUNCH
ABUS
Arbutus Biopharma Corp
2.93UNCHUNCH
SVA
Sinovac Biotech Ltd
6.47-0.02-0.31%
TH
Target Hospitality Corp
16.98UNCHUNCH
ONC